pharmaphorum

APRIL 20, 2021

NICE’s final appraisal document for Kesimpta will be followed by technology appraisal guidance (TAG) that will pave the way for NHS prescribing in England and Wales. billion by 2028. billion in sales in 2028. The Scottish Medicines Consortium is expected to publish its final advice on the drug later this year.

Hospitals 111

Hospitals Documentation 111

European Pharmaceutical Review

NOVEMBER 14, 2023

In the document, it was reasoned that global shortage of these vials threatened the delivery of COVID-19 vaccines and availability of existing parenteral products. Europe’s pharmaceutical packaging market to value over $35bn by 2028 The post USP General Chapter <660>—Glass revised appeared first on European Pharmaceutical Review.

Packaging 105

Packaging Vaccines Documentation FDA 105

European Pharmaceutical Review

DECEMBER 19, 2023

The workplan, which runs until 2028, will help the European medicines regulatory network (EMRN) embrace the opportunities of AI for personal productivity, automating processes and systems, increasing insights into data and supporting more robust decision-making to benefit public and animal health.

Packaging 105

Packaging Documentation 105

Pharmaceutical Technology

SEPTEMBER 15, 2022

According to GlobalData’s report, Paxlovid, the company’s small-molecule Covid-19 oral therapy, was shown to reduce Covid-19 infections by 32% in adults and is forecast to be the top-selling drug by total sales, generating $81bn between 2021 and 2028. Bristol Myers Squibb (BMS) documented a 9.1% AbbVie reported a 22.7%

Vaccines 108

Vaccines Documentation Compounding FDA 108

PQA

APRIL 26, 2023

PQA has a new frequently asked questions (FAQ) document that addresses background and basics of SDS risk adjustment and PQA’s risk adjustment recommendations for the three adherence measures in Medicare Part D (PDC-Diabetes All Class, PDC-Renin Angiotensin System Antagonists, and PDC-Statins).

Documentation 40

Documentation 40

Pharmaceutical Technology

MARCH 30, 2023

billion in 2028. There, the FDA suggested that the drugs undergo randomised controlled trials, which the document describes as the preferred approach, rather than single-arm trials. In 2022, the company reported Keytuda sales of $20.9 billion in its FY 2022 results. GlobalData is the parent company of Pharmaceutical Technology.

Chemotherapy 52

Chemotherapy Packaging FDA Documentation 52

Impact Pharmaceutical Services

SEPTEMBER 15, 2023

billion by 2028. Process reliability and product consistency are critical during scaling up to commercial production, necessitating comprehensive documentation of process parameters, analytic results, and manufacturing data. New methodologies provide insights into protein thermal stability across the proteome and in biological systems.

Documentation 59

Documentation Process Improvement Compounding 59